DR. MATTHEW KENT TOPHAM, M.D.
Osteopathic Medicine at Circle Of Hope Dr, Salt Lake City, UT
License number
Utah 275053-1205
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Utah 275053-1205
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
2000 Circle Of Hope Dr ROOM 5363, Salt Lake City, UT 84112
Phone
(801) 585-0304
Personal information
See more information about MATTHEW KENT TOPHAM at radaris.comName
Address
Phone
1974 E Hubbard Ave, Salt Lake City, UT 84108
1974 Hubbard Ave, Salt Lake Cty, UT 84108
3785 W 1400 N, Cedar City, UT 84721
730 N 400 E, Richfield, UT 84701
730 400, Richfield, UT 84701
Professional information
Method Of Screening For Agents That Regulate The Shedding Of Membrane Bound Proteins And Methods Of Use
US Patent:
7241570, Jul 10, 2007
Filed:
Mar 22, 2002
Appl. No.:
10/471122
Inventors:
Stephen M. Prescott - Salt Lake City UT, US
Matthew Topham - Salt Lake City UT, US
Fumio Sakane - Sapporo, JP
Akinobu Taketomi - Nakatsu, JP
Matthew Topham - Salt Lake City UT, US
Fumio Sakane - Sapporo, JP
Akinobu Taketomi - Nakatsu, JP
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/48, C12Q 1/68
US Classification:
435 6, 435 15
Abstract:
The present invention provides a method of screening for agents which may regulate or inhibit the activities of TACE and TGF-α. These agents may act by enhancing or inhibiting the activity of DGK-δ. An activity of DGK-δ is the enzymatic conversion of DAG to PA. The method includes contacting a cell or organism with a test agent determining the activity of DGK-δ within the cell. An agent with reduces or increases the activity of DGK may be used to regulate or inhibit the activity of TACE and TGF-α. Such agents can be used to treat diseases such as cancer where cell growth and division and inflamation are important factors.
Matthew Topham, Salt Lake City UT
Work:
Uumc Pulmonary Dept
50 N Medical Dr, Salt Lake City, UT 84132 Huntsman Cancer Institute
2000 Circle Of Hope Dr, Salt Lake City, UT 84112 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148
50 N Medical Dr, Salt Lake City, UT 84132 Huntsman Cancer Institute
2000 Circle Of Hope Dr, Salt Lake City, UT 84112 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148
Neuroprotection By Inhibition Of Diacyglycerol Kinase Epsilon Activity
US Patent:
2004013, Jul 8, 2004
Filed:
Sep 8, 2003
Appl. No.:
10/471116
Inventors:
Stephen Prescott - Salt Lake City UT, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena B Rodriguez de Turco - New Orleans LA, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena B Rodriguez de Turco - New Orleans LA, US
International Classification:
A61K049/00, C12Q001/48
US Classification:
435/015000, 424/009200
Abstract:
The present invention includes the characterization of the DGKe gene and the generation of screening methods for compounds that inhibit the function of DGKe. The DGK family of enzymes occupies a signaling crossroads since they catalyze the phosphorylation of DAG to produce PA. Both the substrate (DAG) and the product (PA) of this reaction are key factors in intracellular signaling, making the regulation of DGKe activity important to understand and control. DGKe -/- mice were also generated and studied to assist in understanding the function of DGKs in regulating cellular signaling. DGKe displays selectively for 20:4-DAG and is highly expressed in different areas of the brain, including Purkinje cells in the cerebellum, hippocampal interneurons, and the Pyramidal neurons in the CA3 region of the hippocampus.
Neuroprotection By Inhibition Of Diacyglycerol Kinase Epsilon Activity
US Patent:
2007016, Jul 12, 2007
Filed:
Feb 23, 2007
Appl. No.:
11/710067
Inventors:
Stephen Prescott - Solt Lake City UT, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena Rodriguez de Turco - New Orleans LA, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena Rodriguez de Turco - New Orleans LA, US
International Classification:
A61K 31/66, C12Q 1/48
US Classification:
435015000, 514102000
Abstract:
The present invention includes the characterization of the DGKε gene and the generation of screening methods for compounds that inhibit the function of DGKε. The DGK family of enzymes occupies a signaling crossroads since they catalyze the phosphorylation of DAG to produce PA. Both the substrate (DAG) and the product (PA) of this reaction are key factors in intracellular signaling, making the regulation of DGKε activity important to understand and control. DGKε −/− mice were also generated and studied to assist in understanding the function of DGKs in regulating cellular signaling. DGKε displays selectively for 20:4-DAG and is highly expressed in different areas of the brain, including Purkinje cells in the cerebellum, hippocampal interneurons, and the Pyramidal neurons in the CA3 region of the hippocampus.
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
US Patent:
5976875, Nov 2, 1999
Filed:
Apr 22, 1997
Appl. No.:
8/841483
Inventors:
Stephen M. Prescott - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Assignee:
University of Utah - Salt Lake City UT
International Classification:
C12N 120, C07H 2104
US Classification:
435325
Abstract:
Two novel diacylglycerol kinase (DGK) isoforms are disclosed. The cDNA of one DGK isoform, designated DGK. epsilon. , is about 2. 6 kb in length. The DGK. epsilon. cDNA has an open reading frame encoding 567 amino acids and has a predicted molecular mass of 63 kDA. DAG kinase. epsilon. is highly selective for arachidonate-containing diacylglycerol (DAG) substrates. The cDNA of the second isoform, designated DGK. zeta. , is 3. 5 kb in length. The DGK. zeta. cDNA contains a single large open reading frame encoding a 928-amino acid protein with a predicted molecular mass of 103. 9 kDa. An alternatively spliced muscle specific species of DGK. zeta. , DGK. zeta. -2 is also disclosed and characterized. DGK. zeta. is localized to the nucleus. A lysine-rich region with homology to the MARCKS protein is shown to be necessary and sufficient to confer nuclear localization to DGK. zeta.
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
US Patent:
6221658, Apr 24, 2001
Filed:
Aug 25, 1999
Appl. No.:
9/382911
Inventors:
Stephen M. Prescott - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 502, C12N 120, C07H 2104
US Classification:
435325
Abstract:
Two novel diacylglycerol kinase (DGK) isoforms are disclosed. The cDNA of one DGK isoform, designated DGK. epsilon. , is about 2. 6 kb in length. The DGK. epsilon. cDNA has an open reading frame encoding 567 amino acids and has a predicted molecular mass of 63 kDA. DAG kinase. epsilon. is highly selective for arachidonate-containing diacylglycerol (DAG) substrates. The cDNA of the second isoform, designated DGK. zeta. , is 3. 5 kb in length. The DGK. zeta. cDNA contains a single large open reading frame encoding a 928-amino acid protein with a predicted molecular mass of 103. 9 kDa. An alternatively spliced muscle specific species of DGK. zeta. , DGK. zeta. -2 is also disclosed and characterized. DGK. zeta. is localized to the nucleus. A lysine-rich region with homology to the MARCKS protein is shown to be necessary and sufficient to confer nuclear localization to DGK. zeta.